These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

593 related items for PubMed ID: 29028121

  • 1. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
    Shao K, McGettigan S, Elenitsas R, Chu EY.
    J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
    [Abstract] [Full Text] [Related]

  • 2. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
    Parakh S, Nguyen R, Opie JM, Andrews MC.
    Australas J Dermatol; 2017 Aug; 58(3):e109-e112. PubMed ID: 27170423
    [Abstract] [Full Text] [Related]

  • 3. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.
    Blakeway EA, Elshimy N, Muinonen-Martin A, Marples M, Mathew B, Mitra A.
    Melanoma Res; 2019 Jun; 29(3):338-341. PubMed ID: 30762712
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
    Wang LL, Patel G, Chiesa-Fuxench ZC, McGettigan S, Schuchter L, Mitchell TC, Ming ME, Chu EY.
    JAMA Dermatol; 2018 Sep 01; 154(9):1057-1061. PubMed ID: 30027278
    [Abstract] [Full Text] [Related]

  • 6. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
    Marano AL, Clarke JM, Morse MA, Shah A, Barrow W, Selim MA, Hall RP, Cardones AR.
    Br J Dermatol; 2019 Sep 01; 181(3):580-583. PubMed ID: 30244487
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Grover's-like drug eruption under anti-PD-1 therapy for metastatic melanoma].
    Amini-Adle M, Balme B, Dalle S.
    Ann Dermatol Venereol; 2018 Dec 01; 145(12):802-803. PubMed ID: 30415933
    [No Abstract] [Full Text] [Related]

  • 9. Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients.
    Nardin C, Jeand'heur A, Bouiller K, Valnet-Rabier MB, Dresco F, Castagna J, Mareschal A, Carlet C, Nerich V, Limat S, Puzenat E, Aubin F.
    J Am Acad Dermatol; 2020 Mar 01; 82(3):770-772. PubMed ID: 31734192
    [No Abstract] [Full Text] [Related]

  • 10. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
    Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S, Carlino MS, Kefford R, Fernandez-Penas P.
    J Am Acad Dermatol; 2016 Mar 01; 74(3):455-61.e1. PubMed ID: 26793994
    [Abstract] [Full Text] [Related]

  • 11. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma.
    Woodbeck R, Metelitsa AI, Naert KA.
    Am J Dermatopathol; 2018 Jul 01; 40(7):523-526. PubMed ID: 29924748
    [Abstract] [Full Text] [Related]

  • 12. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
    Berger M, Legeay AL, Souci S, Streichenberger N, Thomas L, Dalle S.
    Eur J Cancer; 2018 Nov 01; 104():227-230. PubMed ID: 30322679
    [No Abstract] [Full Text] [Related]

  • 13. Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
    Arianayagam S, Ieremia E, Matin RN.
    Eur J Dermatol; 2019 Jun 01; 29(3):349-351. PubMed ID: 31389799
    [No Abstract] [Full Text] [Related]

  • 14. Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies.
    Hwang SJ, Carlos G, Chou S, Wakade D, Carlino MS, Fernandez-Penas P.
    Melanoma Res; 2016 Aug 01; 26(4):413-6. PubMed ID: 27031539
    [Abstract] [Full Text] [Related]

  • 15. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.
    Mochel MC, Ming ME, Imadojemu S, Gangadhar TC, Schuchter LM, Elenitsas R, Payne AS, Chu EY.
    J Cutan Pathol; 2016 Sep 01; 43(9):787-91. PubMed ID: 27161449
    [Abstract] [Full Text] [Related]

  • 16. [Two cases of granuloma annulare under anti-PD1 therapy].
    Charollais R, Aubin F, Roche-Kubler B, Puzenat E.
    Ann Dermatol Venereol; 2018 Feb 01; 145(2):116-119. PubMed ID: 29221649
    [Abstract] [Full Text] [Related]

  • 17. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.
    Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM.
    Eur J Cancer; 2016 Jun 01; 60():190-209. PubMed ID: 27085692
    [Abstract] [Full Text] [Related]

  • 18. Anti-PD-1-associated organizing pneumonia in a responding melanoma patient.
    Fiset PO, Shapera S, Butler MO, Tsao MS.
    Ann Oncol; 2016 Aug 01; 27(8):1649-50. PubMed ID: 27091805
    [No Abstract] [Full Text] [Related]

  • 19. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V.
    Am J Clin Dermatol; 2018 Jun 01; 19(3):345-361. PubMed ID: 29256113
    [Abstract] [Full Text] [Related]

  • 20. Uveal Effusion After Immune Checkpoint Inhibitor Therapy.
    Thomas M, Armenti ST, Ayres MB, Demirci H.
    JAMA Ophthalmol; 2018 May 01; 136(5):553-556. PubMed ID: 29677240
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.